Daily Sepsis Research Analysis
Analyzed 67 papers and selected 3 impactful papers.
Summary
Analyzed 67 papers and selected 3 impactful articles.
Selected Articles
1. Targeting phenol-soluble modulin α3-driven M1 macrophage polarization and necroptosis mitigates MRSA infection in mice.
This study uncovers a PSMα3–FPR2–ISGF3 axis that drives M1 polarization and necroptosis in MRSA pathogenesis and shows that fludarabine, a STAT1 inhibitor, reduces MRSA burden and improves outcomes in murine sepsis and pneumonia models. It establishes anti-virulence, host-directed therapy as a promising approach against MRSA.
Impact: It provides a mechanistic foundation for repurposing a clinically available drug to counter MRSA in sepsis via anti-virulence pathways, addressing a major unmet need in antimicrobial resistance.
Clinical Implications: While preclinical, the results support evaluation of STAT1-targeted, host-directed adjunctive therapy for severe MRSA sepsis, with careful dose–toxicity assessment given fludarabine’s immunosuppressive profile.
Key Findings
- PSMα3 induces M1 macrophage polarization and necroptosis via FPR2 engagement.
- ISGF3–necrosome crosstalk mechanistically links polarization and necroptosis.
- Pharmacologic STAT1 inhibition with fludarabine mitigates MRSA infection in murine sepsis and pneumonia.
- Findings support anti-virulence, host-directed strategies against MRSA.
Methodological Strengths
- Mechanistic dissection across receptor (FPR2), signaling (ISGF3/STAT1), and cell death pathways (necroptosis).
- Efficacy demonstrated in multiple in vivo models (murine sepsis and pneumonia).
Limitations
- Preclinical murine models may not fully recapitulate human MRSA sepsis.
- Fludarabine’s immunosuppression and optimal dosing window were not clinically evaluated.
Future Directions: Translate findings into dose-ranging safety and efficacy studies of STAT1-targeted adjuncts in severe MRSA infections; explore biomarker-guided selection (e.g., PSMα3/FPR2 activity) for patient stratification.
The growing antibiotic resistance and high mortality rates associated with methicillin-resistant Staphylococcus aureus (MRSA) pose a global health threat, highlighting the urgent need for novel therapeutic strategies. Phenol-soluble modulin α3 (PSMα3) is a critical virulence factor in MRSA pathogenesis and immune evasion. However, its underlying mechanisms remain unclear. Here, we demonstrate that PSMα3 promotes both M1 macrophage polarization and necroptosis. These processes are mechanistically linked through an interaction between the interferon-stimulated gene factor 3 (ISGF3) and necrosome complexes, with formyl peptide receptor 2 (FPR2) serving as the key receptor. Based on this mechanism, we show that targeting signal transducer and activator of transcription 1 (STAT1), a key component of the ISGF3 complex, with the clinically approved drug fludarabine effectively mitigates MRSA infection in murine sepsis and pneumonia models. These findings reveal the mechanisms of MRSA pathogenesis and highlight the potential of anti-virulence strategies as innovative therapeutic approaches against MRSA infections.
2. Lactylation of histone H3K18 promotes autophagic gene expression to mitigate immunosuppression in sepsis.
The study identifies H3K18 lactylation as a key epigenetic mark coupling glycolysis to autophagy gene expression (ATG5/ATG16L1) in sepsis-induced immunosuppression. Lactate supplementation restores H3K18la and autophagic flux, improving bactericidal function; genetic disruption (H3K18R) abrogates rescue.
Impact: This work uncovers a first-in-class metabolic–epigenetic checkpoint driving immunosuppression in sepsis, spotlighting histone lactylation as a therapeutic axis.
Clinical Implications: Although preclinical, it suggests therapeutic strategies that restore lactylation or directly augment autophagy (e.g., metabolic support, targeted epigenetic modulation) in immunosuppressed sepsis phenotypes.
Key Findings
- Glycolytic dysfunction reduces H3K18 lactylation, silencing autophagy in sepsis models.
- H3K18la directly regulates ATG5 and ATG16L1 transcription (CUT&Tag-seq).
- Lactate supplementation restores H3K18la, autophagic flux, and bactericidal function.
- H3K18R mutation blocks lactate-mediated rescue; ATG5/ATG16L1 overexpression bypasses H3K18la deficiency.
Methodological Strengths
- Integration of in vitro LPS tolerance and in vivo CLP immunosuppression models.
- Causal validation via CUT&Tag-seq, metabolite rescue, and histone point mutation.
Limitations
- Translation to human sepsis remains untested; inter-species epigenetic differences may affect applicability.
- Systemic lactate therapy may have hemodynamic and metabolic trade-offs requiring careful titration.
Future Directions: Define patient subphenotypes with low lactylation/autophagy for precision trials; explore small-molecule modulators of histone lactylation and autophagy synergy in clinically relevant models.
Sepsis-induced immunosuppression is associated with both autophagy impairment and glycolytic dysfunction. However, it is unclear how metabolic dysfunction drives epigenetic reprogramming, thereby reducing autophagy in sepsis. Here, we demonstrate that glycolytic dysfunction and consequent lactate deficiency epigenetically silence autophagy by reducing histone H3 lysine 18 lactylation (H3K18la). Using LPS-tolerant macrophages and CLP-induced immunosuppressive murine models, we observed that reduced lactate levels and global lactylation correlated with impaired autophagic flux and diminished bacterial clearance, with H3K18la emerging as the most consistently downregulated histone lactylation mark. Mechanistically, CUT&Tag-seq revealed ATG5 and ATG16L1 as direct transcriptional targets of H3K18la. Moreover, lactate supplementation restored H3K18la deposition, upregulated ATG5/ATG16L1 expression, and rescued autophagy and bactericidal function. Then a lactylation-deficient H3K18R mutation abolished lactate-mediated rescue, while overexpression of ATG5/ATG16L1 restored autophagy even under H3K18la-deficient conditions. Overall, these findings implicate H3K18la as a metabolic-epigenetic checkpoint linking glycolysis to autophagy gene expression, providing a mechanistic framework for understanding how metabolic dysfunction may contribute to immunosuppression in sepsis.
3. Dynamic gut responses to sepsis uncovered by multi-omics profiling in a rodent model.
A longitudinal, integrative multi-omics atlas of the gut during rodent pneumonia-induced sepsis reveals coordinated temporal shifts in immune and structural cells, microbiota, metabolites, and proteins. The work delineates cross-domain fluctuation patterns and suggests candidate pathways for host–microbiome–immune modulation.
Impact: It provides a systems-level, time-resolved framework linking gut cell states, microbiota, and metabolites during sepsis, enabling hypothesis generation for targeted interventions.
Clinical Implications: Translational leads include timing and pathway-specific modulation of gut immunity and microbiota; findings can inform design of stage-adapted therapeutics and biomarker panels.
Key Findings
- Mononuclear phagocytes and T cells undergo compositional and transcriptional shifts during sepsis.
- Structural and mucus-producing cells adopt roles in antigen presentation and homeostasis regulation.
- Gut microbiome, metabolites, and colonic proteins show shared, time-resolved fluctuation patterns.
- Cross-domain integration highlights candidate therapeutic targets for host–microbiome–immune modulation.
Methodological Strengths
- Longitudinal, multi-omics integration (cellular, microbiome, metabolome, proteome).
- Time-resolved analysis enabling cross-domain fluctuation mapping.
Limitations
- Rodent pneumonia-induced model may not generalize to all human sepsis etiologies.
- Causal links between specific microbiota/metabolites and outcomes require perturbational validation.
Future Directions: Interventional studies to perturb candidate pathways (e.g., targeted microbiome or metabolite modulation) at defined time windows; translation to human cohorts with matched multi-omics and outcomes.
Sepsis reflects an immune dysregulation in response to infection, and the intestine functions as the largest immune organ in the human body. However, the multidimensional dynamic changes within the gut environment during the progression of sepsis remain incompletely understood. Here, we show the alterations in the gut over the course of pneumonia-induced sepsis through the analysis of cellular, microbial, metabolic, and protein profiles over time. We demonstrate that subsets of immune cells, including mononuclear phagocytes and T cells, undergo compositional and transcriptional shifts. Simultaneously, specific structural cells and mucus-producing cells exhibit adapted roles in antigen presentation and the regulation of intestinal homeostasis. Furthermore, we detail alterations in the gut microbiome composition, metabolite levels, and colonic protein expression, identifying shared fluctuation patterns across these biological dimensions. These findings outline the interactions among the gut microbiome, cellular activity, and immune responses, providing potential therapeutic targets for future sepsis management.